<DOC>
	<DOCNO>NCT02155660</DOCNO>
	<brief_summary>The purpose study determine benralizumab reduces COPD exacerbation rate symptomatic patient moderate severe COPD receive standard care therapy .</brief_summary>
	<brief_title>Efficacy Safety Benralizumab Moderate Very Severe Chronic Obstructive Pulmonary Disease ( COPD ) With Exacerbation History</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>. Informed consent . Subjects 4085 y.o . Moderate severe COPD Post Bronchodilator ( BD ) FEV1 &gt; 20 % ≤65 % . ≥2 moderate ≥1 severe COPD exacerbation ( ) require treatment hospitalization within 252 week prior Visit1 . Modified Medical Research Council ( mMRC ) score ≥1 Visit 1 . Treatment double triple therapy throughout year prior Visit 1 , constant 2 week prior Visit 1 . Tobacco history ≥10 packyears . Women childbearing potential must use highly effective form birth control Visit 1 16 week last dose , negative serum pregnancy test result Visit 1 . Male subject sexually active must surgically sterile one year prior Visit 1 use adequate method contraception first Investigational Product ( IP ) dose 16 week last dose . Compliance maintenance therapy runin ≥70 % . Blood eosinophil due subject 's stratification cap blood eosinophil levels.When eosinophil cohort full , subject complete cohort randomise withdrawn study . Exclusion criterion : Clinically important pulmonary disease COPD another diagnose pulmonary systemic disease associate elevated peripheral eosinophil count . Any disorder major physical impairment stable Investigator opinion and/or could affect : subject safety−study finding interpretation subject 's ability complete entire study duration . Unstable ischemic heart disease , arrhythmia , cardiomyopathy , relevant cardiovascular disorder Investigator 's judgment may put patient risk negatively affect study outcome . Treatment systemic corticosteroid and/or antibiotic , and/or hospitalization COPD exacerbation within 2 week prior Visit1 enrolment runin period . Acute upper low respiratory infection require antibiotic within 2 week prior Visit1 enrolment runin period . Pneumonia within 8 week prior Visit1 enrolment runin period . Pregnant , breastfeeding , lactate woman . Risk factor pneumonia History anaphylaxis biologic therapy . Long term oxygen therapy sign and/or symptom cor pulmonale , right ventricular failure . Use immunosuppressive medication within 2 week prior Visit1 and/or enrolment runin period . Receipt investigational nonbiologic product within 30 day 5 halflives prior Visit 1 . Evidence active tuberculosis ( TB ) without appropriate course treatment . Lung volume reduction surgery within 6 month prior Visit 1 . History partial total lung resection ( single lobe segmentectomy acceptable ) . Asthma primary main diagnosis accord Global Initiative Asthma ( GINA ) guideline accept guideline . Previous treatment benralizumab . Helminth parasitic infection diagnose within 24 week prior Visit 1 .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Obstructive Lung Diseases</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>Lung Disease</keyword>
	<keyword>Bronchial Diseases</keyword>
	<keyword>COPD Exacerbation</keyword>
	<keyword>Respiratory Tract Diseases</keyword>
</DOC>